Akums Drugs and Pharmaceuticals IPO Details Today : Akums Drugs and Pharmaceuticals IPO is Open on 30 July 2024 and Close on 1 August 2024. Akums Drugs and Pharmaceuticals IPO to Raise 27,345,162 shares (Appprox ₹1,856.74 Cr) via IPO. The Fresh issue of 10,014,727 shares (Approx ₹680.00 Cr) and The Offer For Sale is 17,330,435 shares of ₹2 (Approx ₹1,262.83 Cr).
Established in 2004, we are a pharmaceutical contract development and manufacturing organization (“CDMO”) offering a comprehensive range of pharmaceutical products and services in India and overseas. As one of the leading CDMOs in India, we own the intellectual property for the manufacturing processes of several of our formulations, and our core business is focused on providing end-to-end product development and manufacturing solutions to our Clients.
Some of our other services include formulation research and development (“R&D”), preparation and filing of regulatory dossiers in the Indian and global markets, and other testing services. In addition to our core CDMO business. we are also engaged in the manufacturing and sale of branded pharmaceutical formulations and active pharmaceutical ingredients (“APIs”) .
We produce an extensive range of dosage forms including tablets, capsules, liquid orals, vials, ampoules, blow-filled seals, topical preparations, eye drops, dry powder injections, and gummies, among others. we have manufactured 4,025 commercialised formulations across over 60 dosage forms.
key clients for our CDMO business include Alembic Pharmaceuticals, Alkem Laboratories, Blue Cross Laboratories, Cipla, Dabur India, Dr. Reddy’s Laboratories, Hetero Healthcare, Ipca Laboratories, Mankind Pharma, MedPlus Health Services, Micro Labs, Mylan Pharmaceuticals, Natco Pharma, Sun Pharmaceutical Industries, UCB, and Amishi Consumer Technologies (The Mom’s Co), among others.
Our international presence extends across 60 countries, and our key clients include Allegens (Vietnam), Ambica International (Philippines), Caferma SAC (Peru), JDS (Myanmar), Master Pharma (Cambodia), Olainfarm (Latvia), Pharma Apex (Myanmar), Planet Pharmaceutical (Tanzania), and Unisel (Kenya), among others.
Akums Drugs and Pharmaceuticals IPO Date & Price Band Details
IPO Open Date
30 July 2024
IPO Close Date
1 August 2024
IPO Size
27,345,162 shares (Appprox ₹1,856.74 Cr)
Fresh Issue
10,014,727 shares (Approx ₹680.00 Cr)
Offer For Sale
17,330,435 shares of ₹2 (Approx ₹1,262.83 Cr)
Lot Size
22 Shares
IPO Face Value
₹2 Per Equity Share"
IPO Price Band
₹646 to ₹679 Per Every Share
Employee Discount
₹64 Per Equity Shares
IPO Listing On
NSE & BSE
IPO Retail Quota
10%
IPO QIB Quota
75%
IPO NII Quota
15%
DRHP Draft
Click Here
Anchor Investor
Click Here
Akums Drugs and Pharmaceuticals IPO Market Lot Details
Application
Lot Size
Shares
Amount
Retail Minimum
1
22
₹14,938
Retail Maximum
13
286
₹1,94,194
S-HNI Minimum
14
308
₹2,09,132
S-HNI Maximum
66
1,452
₹9,85,908
B-HNI Minimum
67
1,474
₹10,00,846
Object of the Issue
- Repayment/ prepayment of indebtedness of our Company and its Subsidiaries.
- Funding incremental working capital requirements of our Company.
- Pursuing inorganic growth initiatives through acquisitions.
- General corporate purposes.
Akums Drugs and Pharmaceuticals IPO Allotment & Listings (Details)
IPO Open Date
30 July 2024
IPO Close Date
1 August 2024
Basis of Allotment
2 August 2024
Refunds
5 August 2024
Credit to Demat Account
5 August 2024
IPO Listing Date
6 August 2024
Akums Drugs and Pharmaceuticals Financial Reports
₹ in Crores
Year
Revenue
Expense
PAT
2024
₹4212.21
₹4231.45
₹0.97
2023
₹3700.93
₹3475.93
₹97.82
2022
₹3694.52
₹3874.95
₹250.87
Our Company Promoter
- Sanjeev Jain
- Sandeep Jain
Qualitative Factors
- Largest India-focused CDMO serving the Indian domestic pharmaceutical industry.
- Diverse client base with longstanding CDMO relationships.
- Large and rapidly growing R&D capabilities across our product portfolio.
- Strategic presence across the pharmaceutical value chain.
- Experienced and entrepreneurial management team with a proven track record and marquee healthcare focused PE investor.
Akums Drugs and Pharmaceuticals IPO Comparison Listed Industry Peers Group
| Company Name | Face Value | EPS | P/E Ratio | Ro NW (%) | NAV Per | Revenue (₹ in Lakhs) |
|---|---|---|---|---|---|---|
| Akums Drugs and Pharmaceuticals | 2.00 | 6.63 | [.] | 13.23% | 50.13 | 36,548.20 |
| Peer Group | ||||||
| Divi's Laboratories | 2.00 | 68.69 | 53.86 | 14.28% | 480.93 | 77,675.10 |
| Suven Pharma | 1.00 | 16.16 | 40.41 | 23.70% | 68.16 | 13,403.30 |
| Gland Pharma | 1.00 | 47.44 | 42.55 | 9.81% | 483.41 | 36,246.01 |
| Torrent Pharma | 5.00 | 36.79 | 71.86 | 20.09% | 183.13 | 96,201.50 |
| Alkem Laboratories | 2.00 | 82.31 | 59.82 | 10.88% | 756.52 | 1,15,992.60 |
| Eris Lifesciences | 10.00 | 28.10 | 31.56 | 17.40% | 161.49 | 16,851.49 |
| JB Chemicals | 2.00 | 53.00 | 32.64 | 16.52% | 320.77 | 31,492.82 |
| Mankind Pharma | 1.00 | 32.00 | 64.30 | 17.24% | 185.61 | 87,494.33 |
| Innova Captab | 10.00 | 14.16 | 37.91 | 24.58% | 57.61 | 9,263.80 |
Comparison of accounting ratios with Listed Industry Peers
- Akums Drugs and Pharmaceuticals
- Divi’s Laboratories
- Suven Pharma
- Gland Pharma
- Torrent Pharma
- Alkem Laboratories
- Eris Lifesciences
- JB Chemicals
- Mankind Pharma
- Innova Captab
Also Read: Bansal Wire Industries IPO details, Date, Price, GMP, Review
Akums Drugs and Pharmaceuticals Company Contact Details
304 Mohan Place
LSC Saraswati Vihar
Delhi -110 034, India
Tel: +91 11 6904 1000
E-mail:cs@akums.net
Website: www.akums.in
Akums Drugs and Pharmaceuticals IPO Registrar
Link Intime India Private Limited
C-101, 1stFloor, 247 Park,
Lal Bahadur Shastri Marg, Vikhroli (West)
Mumbai -400 083
Maharashtra, India
Tel:+91 810 811 4949
E-mail:akumsdrugs.ipo@linkintime.co.in
Website:www.linkintime.co.in
Investor grievance e-mail:akumsdrugs.ipo@linkintime.co.in
Contact person:Shanti Gopalkrishnan
4 thoughts on “Akums Drugs & Pharmaceuticals IPO Details Today, GMP Price”